Valeant Pharmaceuticals International Investor Relations Manager Salary | Comparably
Valeant Pharmaceuticals International develops and markets medications used in the fields of neurology, dermatology and infectious diseases. read more
EMPLOYEE
PARTICIPANTS
8
TOTAL
RATINGS
107

Valeant Pharmaceuticals International Investor Relations Manager Salary

The average Valeant Pharmaceuticals International Investor Relations Manager earns an estimated $95,755 annually. Valeant Pharmaceuticals International's Investor Relations Manager compensation is $8,452 more than the US average for a Investor Relations Manager.

The Communications Department at Valeant Pharmaceuticals International earns $17,064 more on average than the Enterprise Risk Department.

Last updated 2 years ago.

$51k
$64k
$75k
$85k
$114k
$175k
$95,755
Average Compensation
$95,755
avg. base

Investor Relations Manager Salaries at Valeant Pharmaceuticals International

* estimated salary

Compensation at Valeant Pharmaceuticals International by Department

The Communications Department averages $17,064 more than the Enterprise Risk Department.

Communications
$192,901 Avg. total comp.
Enterprise Risk
$175,837 Avg. total comp.
-$17k
Product
$162,740 Avg. total comp.
-$30k

Investor Relations Manager Compensation by Gender (All Companies)

The average female Investor Relations Manager at companies similar size to Valeant Pharmaceuticals International reported making $152,500, while the average male Investor Relations Manager at similar sized companies reported making $75,500.

Investor Relations Manager Compensation by Ethnicity (All Companies)

The average Asian or Pacific Islander Investor Relations Manager at companies similar size to Valeant Pharmaceuticals International reported making $175,000, while the average Caucasian Investor Relations Manager at similar sized companies reported making $70,250.

How Investor Relations Managers at Valeant Pharmaceuticals International Rate Their Compensation

The majority of Investor Relations Managers at Valeant Pharmaceuticals International believe they're compensated fairly. The vast majority (80%) of Investor Relations Managers at Valeant Pharmaceuticals International are satisfied with their benefits. See more compensation ratings at Valeant Pharmaceuticals International

×
Rate your company